Menstrual Products Right To Know Act of 2019

H.R. 2268, Menstrual Products Right to Know Act of 2019 (generally, no specific provisions); diaper needs (generally, no specific legislation); access to feminine care products (generally, no specific legislation).

Client expense: $210,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2268, Menstrual Products Right to Know Act of 2019 (generally, no specific provisions); diaper needs (generally, no specific legislation); access to feminine care products (generally, no specific legislation). American Rescue Plan Act of 2021, H.R. 1319, provisions related to personal protective equipment and diapers needs.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2268, Menstrual Products Right to Know Act of 2019 (generally, no specific provisions); diaper needs (generally, no specific legislation); access to feminine care products (generally, no specific legislation).

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation H.R. 535 - The PFAS Action Act of 2019 S.638 - PFAS Action Act of 2019 H.R. 2577 - PFAS Right-to-Know Act H.R. 2268 - Menstrual Products Right To Know Act of 2019 H.R. 7940/S.4406 - Protect Americas Children from Toxic Pesticides Act S.4781 - A bill to direct the Occupational Safety and Health Administration to issue an occupational safety and health standard to protect workers from heat-related injuries and illnesses H.R. 2577 - PFAS Right-to-Know Act Ohio Senate Bill 33 - Modify criminal and civil law for critical infrastructure damage Rulemakings Advanced Notice of Proposed Rulemaking, Addition of Certain Per- and Polyfluoroalkyl Substances; Community Right-to-Know Toxic Chemical Release Reporting. 84 Fed. Reg. 66,369 (December 4, 2019). EPA Proposed Regulations on Transparency in Regulatory Science, 83 Fed. Reg. 18,768 (April 30, 2018). EPA Registration Review; Draft Human Health Risk Assessments for Atrazine, Propazine, and Simazine and Draft Cumulative Human Health Risk Assessment for the Triazines (Atrazine, Propazine, Simazine), 83 Fed. Reg. 35,472 (Jul. 26, 2018) EPA Registration Review; Chlorpyrifos: Third Revised Human Health Risk Assessment for Registration Review, 85 FR 60,455 (Sep. 22, 2020) EPA Proposed Rule, Pesticides; Agricultural Worker Protection Standard; Revision of the Application Exclusion Zone Requirements, 84 Fed. Reg. 58,666 (Nov. 11, 2019) EPA Proposed Rule, Long-Chain Perfluoroalkyl Carboxylate and Perfluoroalkyl Sulfonate Chemical Substances; Significant New Use Rule; Supplemental Proposal, 85 Fed. Reg. 12479 (March 3, 2020). EPA Rule, Implementing Statutory Addition of Certain Per- and Polyfluoroalkyl Substances; Toxic Chemical Release Reporting, 85 Fed. Reg. 37354 (June 22, 2020). EPA Registration Review; Chlorpyrifos: Third Revised Human Health Risk Assessment for Registration Review, 85 Fed. Reg. 60,455 (Sep. 22, 2020) EPA Registration Review; Chlorpyrifos Proposed Interim Registration Review Decision, 85 Fed. Reg. 78,849 (Dec. 7, 2020) EPA Registration Review, Proposed Interim Decision for Paraquat, 85 Fed. Reg. 67,536 (Oct. 23, 2020) EPA Rule, Pesticides; Agricultural Worker Protection Standard; Revision of the Application Exclusion Zone Requirements, 85 Fed. Reg. 68,760 (Oct. 30, 2020) Nominations PN1687 Nancy B. Beck to be Chairman of the Consumer Product Safety Commission

Maternal Health Pandemic Response Act (H.R. 8027) Menstrual Product Right to Know Act (H.R. 2268) The Heroes Act (H.R. 6800) A resolution declaring racism a public health crisis. (S. Res. 655) Expressing the sense of the House that the Department of Justice should defend the Patient Protection and Affordable Care Act (Public Law 111-148; 124 Stat. 119) and halt its efforts to repeal, sabotage, or undermine health care protections for millions of people in the United States in the midst of the public health emergency relating to the Coronavirus Disease 2019 (COVID-19) (H. Res. 1082) HEALS Act (S. 1624) Support and Value Expectant Moms and Babies Act (H.R. 4399/S. 3072) Protect Access to Birth Control Act (H.R. 7517) Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) Prescription Drug Pricing Reduction Act (S. 2543) Worker Health Coverage Protection Act (H.R. 6514) Kids' Access to Primary Care Act (H.R. 6159) Health Care Protection Act (H.R. 6810) Continuous Health Coverage for Workers Act (S. 4929) A resolution expressing the sense of the Senate that the Department of Justice should defend the Patient Protection and Affordable Care Act (Public Law 111-148 Stat. 119) and halt its efforts to repeal, sabotage, or undermine health care protections for millions of people in the United States in the midst of the public health emergency relating to the Coronavirus Disease 2019 (COVID-19). (S. Res. 638) Improving Mental Health Throughout Pregnancy Act (Not yet introduced) Helping MOMS Act of 2020 (H.R. 4996) A bill to protect the healthcare of hundreds of millions of people of the United States and prevent efforts of the Department of Justice to advocate courts to strike down the Patient Protection and Affordable Care Act (S. 4653) A bill to preserve health benefits for workers (S. 4714) America's Conservation Enhancement Act [The Heroes Act] (H.R. 925)

H.R. 2268, Menstrual Products Right to Know Act of 2019 (generally, no specific provisions); diaper needs (generally, no specific legislation); access to feminine care products (generally, no specific legislation).

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2268, Menstrual Products Right to Know Act of 2019 (generally, no specific provisions); diaper needs (generally, no specific legislation); access to feminine care products (generally, no specific legislation).

Client expense: $180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2268, Menstrual Products Right to Know Act of 2019 (generally, no specific provisions); diaper needs (generally, no specific legislation); access to feminine care products (generally, no specific legislation).

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE